News
ITCI
--
0.00%
--
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15)
Benzinga · 1d ago
Here's Why We Think Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Compensation Looks Fair for the time being
Performance at Intra-Cellular Therapies, Inc. ( NASDAQ:ITCI ) has been reasonably good and CEO Sharon Mates has done a...
Simply Wall St. · 2d ago
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10)
Benzinga · 6d ago
The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9)
Benzinga · 06/10 12:13
Stocks That Hit 52-Week Highs On Wednesday
    During Wednesday's morning trading, 251 companies set new 52-week highs.
Benzinga · 06/09 14:05
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7)
Benzinga · 06/08 13:17
Looking Into Intra-Cellular Therapies's Return On Capital Employed
During Q1, Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $15.88 million. However, earnings decreased 13.23%, resulting in a loss of $53.22 million. In Q4, Intra-Cellular Therapies brought in $12.45 million in sales but lost $61.33 millio...
Benzinga · 06/07 14:02
CAPLYTA(R) (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology
Pooled analysis of 3 randomized, double-blind, pacebo-cotrolled trials supports the safety and the distinct and favorable tolerability profile of lumateperone 42 mg
GlobeNewswire · 06/07 12:11
Intra-Cellular Therapies Says Co's CAPLYTA Schizophrenia Safety And Tolerability Profile Published In The Journal 'International Clinical Psychopharmacology'
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the article,
Benzinga · 06/07 12:09
Significant Insider Selling in Shares of Intra-Cellular Therapies (ITCI) Continues
MT Newswires · 06/01 22:30
Insider Sale at Intra-Cellular Therapies (ITCI) Continues Selling Trend
MT Newswires · 05/31 22:20
Insider Trends: Insider Prolongs 90-Day Selling Trend at Intra-Cellular Therapies
MT Newswires · 05/28 18:07
Insider Sale at Intra-Cellular Therapies (ITCI) Deemed Significant
MT Newswires · 05/26 22:34
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Ch...
GlobeNewswire · 05/26 12:09
Insider Trends: Selling By Insiders Lingers at Intra-Cellular Therapies
MT Newswires · 05/25 18:10
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24)
Benzinga · 05/25 11:53
Stocks That Hit 52-Week Highs On Monday
    This morning 128 companies set new 52-week highs.
Benzinga · 05/24 14:04
Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI) and Kodiak Sciences (KOD)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intra-Cellular Therapies (ITCI) and Kodiak Sciences (KOD)
SmarterAnalyst · 05/11 12:45
--RBC Boosts Price Target on Intra-Cellular Therapies to $47 From $44, Maintains Outperform Rating
MT Newswires · 05/11 09:11
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 19.75% and 0.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 13:45
Webull provides a variety of real-time ITCI stock news. You can receive the latest news about INTRA CELLULAR through multiple platforms. This information may help you make smarter investment decisions.
About ITCI
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).